There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regulus (RGLS – Research Report), Anavex Life Sciences (AVXL – Research Report) and Apellis Pharmaceuticals (APLS – Research Report) with bullish sentiments.
Regulus (RGLS)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Regulus today and set a price target of $20.00. The company’s shares closed last Monday at $2.10, close to its 52-week low of $1.58.
According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regulus with a $20.00 average price target.
See today’s best-performing stocks on TipRanks >>
Anavex Life Sciences (AVXL)
Berenberg Bank analyst Caroline Palomeque maintained a Buy rating on Anavex Life Sciences today and set a price target of $40.00. The company’s shares closed last Monday at $10.60.
According to TipRanks.com, Palomeque is ranked #7674 out of 7915 analysts.
Anavex Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $35.20.
Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals received a Buy rating and a $75.00 price target from H.C. Wainwright analyst Douglas Tsao today. The company’s shares closed last Monday at $44.76.
According to TipRanks.com, Tsao is a 3-star analyst with an average return of
Apellis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $74.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RGLS:
- Vicon launches new Valkyrie solution
- Defense Contractor Kratos Announces Plan to Add 76 Jobs at its Birmingham Advanced Concepts Engineering Facility
- Truist reports second quarter 2022 results
- Reko Diq Alliance Will Bring Biggest Foreign Investment and Sustainable Prosperity to Balochistan
- Despite Upbeat Q2 Results, Charles Schwab Fails to Impress Investors
